The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase
Phase 1
Started
2026-01-15
Last updated
2026-01-21
Condition(s) studied
Advanced and Relapsed Solid Tumors
Investigational drug(s) / intervention(s)
MST
MST: conventional chemotherapy with microtransplantation(MST). Microtransplantation, which is the infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood mononuclear cells (GPBMC)
Study summary
In this study, microtransplantation (MST) will be administrated to patients diagnosed with advanced / relapsed solid tumors to assess the therapeutic efficacy and safety of conventional chemotherapy in combination with MST for the treatment of advanced/relapsed solid tumors.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients are 18 to 90 years old, regardless of gender or race;
* Advanced / relapsed solid tumors (small cell lung cancer, ovarian cancer, cervical cancer, gastric and colorectal cancer, sarcoma, head and neck tumor, etc.) are confirmed by clinical or histopathological diagnosis;
* More than two kinds of tumors are allowed;
* Karnofsky score ≥ 40, ECoG physical status ≤ 3;
* There are measurable lesions;
Exclusion Criteria:
* The researchers considered patients who were not suitable to participate in this experiment；
* Patients with mental disorders；
* Patients who refuse to cooperate with the treatment；
Primary outcome measure(s)
Treatment-Emergent Adverse Events — 1 month Treatment related mortality
time of hematopoietic recovery — 1 month Absolute neutrophil count \>500/μL; Platelets ≥20,000/μL
Trial sites (3)
Facility
City
Region
Status
Innovvy(Beijing) Biomedical Technology Co., Ltd
Haidian
Beijing Municipality
Minzu Hospital of Guangxi Zhuang Autonomous Region
Nanning
Guangxi
The First People's Hospital of Nanning
Nanning
Guangxi
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.